银丹心脑通软胶囊对心血瘀阻型冠状动脉粥样硬化性心脏病临界病变的影响

目的探讨银丹心脑通软胶囊对心血瘀阻型冠状动脉粥样硬化性心脏病（简称冠心病）临界病变的影响。方法将70例中医辨证为心血瘀阻证的冠心病临界病变患者分为2组各35例，对照组接受冠心病常规治疗，银丹心脑通组在常规治疗基础上加用银丹心脑通。结果银丹心脑通组心肌梗死溶栓疗法（TIMI）危险评分与对照组比较，差异无统计学意义（P〉0．05）。银丹心脑通组高敏C反应蛋白（hs-CRP）水平为（3．2±1．6）mg／L，明显低于对照组的（4．1±2．0）mg／L，差异有统计学意义（P〈0．05）。银丹心脑通组中33例心绞痛症状改善，对照组中27例改善，症状改善率2组间差异有统计学意义（P〈0．05）。2组随访半年时均无主要不良心血管事件（MACE）发生，但对照组中3例因出现心绞痛症状而再住院，银丹心脑通组无再住院情况。结论银丹心脑通可改善心血瘀阻型冠心病临界病变患者心绞痛症状，降低hs-CRP水平，从而减少心绞痛再住院率。

Effects of Yindan Xinnaotong Soft Capsule on borderline lesions of coronary atllerosclerotic heart disease of type of heart-blood stagnation

Objective To observe the effects of Yindan Xinnaotong Soft Capsule on borderline lesions of coronary atheroselerotic heart disease of stagnation of the heart-blood type. Methods Seventy cases of coronary borderline lesion that were diagnosed as TCM type of heart-blood stagnation were divided into 2 groups, 35 cases in each one. Regular treatment was applied in the control group, while regular treatment combined with Yindan Xinnaotong was applied in the treatment group. Results TIMI score in the treatment group was not statistically different from that in the control group （ P 〉 0. 05 ）. Level of high sensitive-CRP was （ 3.2 ±1.6 ） mg/L in the treatment group, which was evidently lower than （4. 1 ± 2. 0） mg/L in the control group （ P 〈 0. 05 ）. There were 33 cases in the treatment group whose clinical symptoms were improved while 27 cases in the control group, indicating statistical differences of improvement rate between two groups （P 〈 0. 05 ）. No major adverse cardiovascular events were found during 6-momth follow-up in two groups, but 3 cases in the control group were re-hospitalized due to angina while none in the treatment were re- hospitalized. Conclusion The Yindan Xinnaotong Soft Capsule could improve angina in patients with coronary atherosclerotic heart disease of type of beart-blood stagnation, lower level of high sensitive-CRP, leading to a low re-hospitalized rate.